Roivant Sciences Chief Accounting Officer Sells Shares

Jennifer Humes, the Chief Accounting Officer at Roivant Sciences Ltd., sold 3,582 shares of the company on June 20, 2026. The transaction was valued at approximately $112,582.26, with shares sold at an average price of $31.43. This sale was not part of a pre-planned trading program.

Insider Buying and Selling at Roivant Sciences Ltd.

On June 20, 2026, Jennifer Humes sold 3,582 shares at $31.43 each, totaling about $112,582.26. This transaction was not part of a Rule 10b5-1 plan. On the same day, CFO Richard Pulik also sold 2,129 shares at the same price. Previously, on May 22, Eric Venker, President & CEO of Immunovant, executed several transactions, both buying and selling shares at different prices.

Other Institutional Activity in Roivant Sciences

Several institutional investors made changes to their holdings in Roivant Sciences recently. FMR LLC increased its position by 12,201,789 shares, now holding a total of 77,981,253 shares valued at approximately $2.16 billion. Morgan Stanley, on the other hand, trimmed its stake by 6,531,228 shares, reducing its total to 51,828,325 shares worth about $1.44 billion. BlackRock, Inc. grew its holdings by 3,083,785 shares, ending with 44,254,260 shares valued at $1.23 billion. UBS Group AG also increased its position by 4,228,680 shares, now holding 22,619,472 shares worth $626.6 million. Vanguard Capital Management LLC opened a new position with 20,680,572 shares, valued at approximately $572.9 million.

Roivant Sciences Ltd. Stock Down 7.2%

Shares of Roivant Sciences Ltd. traded near $31.25 on Wednesday. The company, listed on the NasdaqGS under the ticker ROIV, has a market capitalization of around $22.48 billion. The forward P/E ratio is negative at -20.04, indicating the company is not currently profitable. Roivant's stock has a 52-week range between $10.71 and $32.79. It maintains a 50-day moving average of $29.13 and a 200-day moving average of $23.56. The company's current ratio is notably high at 18.37, with a quick ratio of 17.999, and a debt-to-equity ratio of 2.03.

Analysts Set New Price Targets

Several analysts have recently maintained their ratings on Roivant Sciences. On May 26, 2026, Guggenheim reiterated a "buy" rating with a price target of $36. Citigroup and TD Cowen both maintained their "buy" ratings on May 21, with price targets of $42 and $41, respectively. Piper Sandler also maintained a "buy" rating with a $40 target on April 16. The consensus among 12 analysts is a "strong buy," with an average price target of approximately $39.04.

About Roivant Sciences

Roivant Sciences Ltd. is a biopharmaceutical company based in London, United Kingdom. It focuses on discovering, developing, and bringing to market new medicines and technologies. The company's key programs include treatments for autoimmune diseases, pulmonary hypertension, and other immune-mediated conditions. Founded in 2014, Roivant is led by CEO Matthew Gline and employs around 721 people.

Bottom Line

Jennifer Humes' recent sale of shares in Roivant Sciences reflects ongoing insider activity, which investors often watch closely. Roivant's strategic focus on biotechnology and its robust pipeline make it a company of interest, despite its lack of current profitability. Institutional investors have shown mixed activity, with some increasing and others reducing their stakes. As always, it's important to remember that insider transactions and institutional moves are backward-looking and may not indicate future performance.